Drug Profile
Autologous dendritic cell vaccine - Amphera
Alternative Names: Allogeneic tumour cell lysate pulsed autologous dendritic cells - Amphera; MesoCancerVac; MesoPherLatest Information Update: 12 Jun 2023
Price :
$50
*
At a glance
- Originator Amphera
- Developer Amphera; Erasmus MC
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Mesothelioma
- Phase II Pancreatic cancer
Most Recent Events
- 06 Jun 2023 EMA Committee for Orphan Medicinal Products (COMP) recommends the granting of orphan medicinal product designation for autologous dendritic cells (MesoPher) in pancreatic cancer in European Union
- 26 Jan 2023 Amphera completes the phase II REACtiVe trial in Pancreatic cancer in Netherlands (EudraCT2018-003222-92)
- 12 Dec 2022 Efficacy and safety data from phase II/III DENIM trial in Mesothelioma released by Amphera